There is a reported surge in the use of GLP-1, which may be linked to a decrease in obesity. The surge in GLP-1 is also expected to drive an increase in drug spending and may be impacting various companies, including those in the pharmaceutical and clothing industries. However, the headlines also mention surges and fluctuations in unrelated companies, making it unclear what is specifically driving the GLP-1 surge.